csirt@kutim:~/threat-intel/cve/CVE-2026-48802

Katalog CVE

CVSS 7.5 · High EPSS 0,58%

Kerentanan Allocation of Resources Without Limits or Throttling. Skor CVSS 3.1 7.5 (High) menurut github.com.

Deskripsi (NVD)

python-engineio is a Python implementation of the Engine.IO realtime client and server. Prior to version 4.13.2, an attacker can cause the creation of unnecessary background threads in the python-engineio server by exploiting the heartbeat mechanism, which launches a thread when a new connection is received, and when the client sends a PONG packet. This issue primarily affects synchronous servers. Asynchronous servers allocate background tasks instead of physical threads, which are lightweight and less likely to cause denial of service. However, the fix that was implemented was also applied to the asynchronous case. Version 4.13.2 addresses this issue as follows: The initial background thread (or async task( for heartbeat management is only launched if a client passes authentication in the `connect` handler; and the server now ensures that there is only one background heatbeat thread (or async task) per client at a given point in time. Out of sequence PONG packets are now discarded when an active heartbeat thread is already running.

Rincian

Terbit di NVD
11 Agustus 2026
Terakhir diubah
18 September 2026
Status NVD
Deferred
CVSS 3.1
7.5 (High), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-770: Allocation of Resources Without Limits or Throttling
EPSS (30 hari)
0,58% peluang dieksploitasi; lebih tinggi dari 45,9% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.